|View printer-friendly version|
Mr. Massaro joined Huron Consulting Group as a Managing Director in August 2002. Prior to that time, he was the Managing Partner of Arthur Andersen's 1200-person New England practice. Mr. Massaro has more than 32 years of accounting and auditing experience with expertise in a broad range of areas including: due diligence, transaction structuring, business combinations, complex equity structures, spin-offs and divestitures, revenue recognition, post-acquisition disputes, regulatory consulting, and board and special committee consultation. He has worked with clients in the financial services and high technology industries and has served on American Institute of Certified Public Accountants committees and task forces relating to the development of authoritative literature in both accounting and auditing.
Commenting on Mr. Massaro's election to the Board, James C. Foster, Chairman, President and Chief Executive Officer said, "We are very pleased to welcome George to Charles River Laboratories. His extensive accounting and auditing experience and his business expertise are a valuable addition to our Board of Directors. We look forward to working with him."
Mr. Massaro said, "Charles River Laboratories is an exceptional company with a strong strategic vision. I'm very excited to be joining the Board and to have the opportunity to work with this dynamic management team."
Mr. Massaro is a certified public accountant who received his Bachelor of Science degree in Accounting from Bentley College and his Masters in Business Administration degree from Babson College. He serves on the boards of Jobs for Massachusetts and the Massachusetts Chapter of the National Multiple Sclerosis Society.
Charles River Laboratories, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies. The Company also offers a broad and growing portfolio of biomedical products and services that enable customers to reduce cost, increase speed, and enhance productivity and effectiveness in drug discovery and development. Charles River's customer base spans over 50 countries, and includes all of the major pharmaceutical and biotechnology companies, as well as many leading hospitals and academic institutions. The Company operates 82 facilities in 16 countries worldwide.
Charles River Laboratories (INVESTOR CONTACT)
Susan E. Hardy, 978/658-6000, ext. 1616